Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Recommendation of “Hold” from Brokerages

Carisma Therapeutics, Inc. (NASDAQ:CARM) has been given a consensus recommendation of “Hold” by the seven ratings firms that are covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $4.94.

Several analysts have recently weighed in on CARM shares. HC Wainwright restated a “neutral” rating on shares of Carisma Therapeutics in a report on Monday. Evercore ISI reissued an “in-line” rating and set a $0.70 target price (down from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. D. Boral Capital dropped their price target on shares of Carisma Therapeutics from $24.00 to $12.00 and set a “buy” rating for the company in a research note on Monday, December 9th. BTIG Research cut shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 10th. Finally, Robert W. Baird lowered Carisma Therapeutics from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $10.00 to $1.00 in a research report on Thursday, December 12th.

Carisma Therapeutics Price Performance

Shares of NASDAQ:CARM opened at $0.46 on Thursday. Carisma Therapeutics has a one year low of $0.38 and a one year high of $3.16. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23. The company has a market cap of $19.06 million, a price-to-earnings ratio of -0.29 and a beta of 1.44. The firm has a 50 day simple moving average of $0.87 and a 200 day simple moving average of $1.02.

Carisma Therapeutics (NASDAQ:CARM) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) earnings per share for the quarter, meeting the consensus estimate of ($0.31). The company had revenue of $3.39 million for the quarter. Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. Research analysts predict that Carisma Therapeutics will post -1.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Carisma Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CARM. Barclays PLC raised its position in shares of Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after acquiring an additional 549,290 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Carisma Therapeutics in the second quarter worth approximately $40,000. Wexford Capital LP lifted its stake in Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after buying an additional 15,000 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Carisma Therapeutics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock worth $3,587,000 after buying an additional 11,200 shares in the last quarter. Institutional investors and hedge funds own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.